Skip to content
Screener

Aurinia Pharmaceuticals AUPH Q4 2025 Annual earnings

Reported February 26, 2026 · Before market open

Revenue$77.1MBeat by $2.4M
EPS$0.26Beat by $0.05
Revenue estimate$74.7M
EPS estimate$0.21

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$83.6M
EPS estimate$0.21

Financials

Q4 2025

Income statement

See full
Revenue$77.1M+28.8%
Gross profit$68.3M+25.8%
Operating income$33.2M+2,092%
Net income$210.8M+14,651%
EPS (diluted)$1.53+15,200%

Balance sheet

See full
Cash & equivalents$80.2M-3.9%
Total debt$91.3M-2.2%
Total equity$581.3M+54.0%
Total assets$751.6M+36.5%

Cash flow

See full
Operating cash flow$45.7M+51.7%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$2.1B+63.6%
Enterprise value$2.11B+63.1%
P/E7.3×-216×
P/S7.4×+2.0×

Profitability

See full
Gross margin88.5%+0.5pp
Operating margin37.1%+35.3pp
Net margin101.5%+99.0pp

Returns & leverage

See full
Return on equity59.9%+58.4pp
Debt / equity0.2×-0.1×
Current ratio5.2×+0.7×

FAQ

When did Aurinia Pharmaceuticals report Q4 2025 earnings?
Aurinia Pharmaceuticals (AUPH) reported Q4 2025 earnings on February 26, 2026 before market open.
What were Aurinia Pharmaceuticals's Q4 2025 revenue and EPS?
Aurinia Pharmaceuticals reported revenue of $77.1M and eps of $0.26 for Q4 2025.
Did Aurinia Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $74.7M by $2.4M. EPS beat the consensus estimate of $0.21 by $0.05.
How did Aurinia Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 28.8% from $59.9M a year earlier and eps grew 188.9% from $0.09.
Where can I find Aurinia Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001600620-26-000015) and the 10-K periodic report (0001600620-26-000017) directly on SEC EDGAR. The filing index links above go to sec.gov.